李祝捷丨不惑创投创始合伙人 每日金句 大部分创业者都缺乏全局的产业链思维，但这是所有投资人必须做的基本工 夫。投一家公司之前需要把产业链进行拆解，做行业分析，搞明白产业链上下 游是谁，他们在各个环节里做什么样的事，赚多少钱，每个环节的毛利是多 少。跳出来看看产业链，你会找到创业的答案。 黑马营模式&资本模块主任导师 黑马营 24 期 1 课 这里认真推荐你： 加入 黑马大课年度会员 ，一起做有收获、有成长的创业者！ 主要权益包括 1、全年 8场线下大课 ，任选 3场 参加 2、每场 3天课程 +私董会+小饭桌 现在，早期优惠价： 4980元/人，月底恢复原价 ， 欢迎锁定最后的优惠名额。 活动详情如下 ↓↓↓ 3、全年认识 300位 优秀老板 4、资源链接，进入黑马校友 社群 黑马大课: 14年的积累, 一套符合本土商业基因的创业体系 链接资源: 16年的沉淀,一个追求成长的创始人社群 加入黑马大课年度会员做赢取时代机遇的创业者 核心权益 您将可以在黑马全年8场"黑马大课" 任选3场参加 我们是谁 创业里马 中国创新创业服务第一股 SZ.300688 让创业者不再孤独 --- 2008年,伴着这个初心,创业黑 ...

Core Viewpoint - The Chinese vaccine industry is facing unprecedented challenges in 2024, with significant declines in market value and vaccine issuance, leading to a search for recovery strategies amidst a harsh environment [1] Group 1: Market Dynamics - The total market value of 11 A-share vaccine companies is less than the peak value of Zhifei Biological three years ago [1] - The issuance of HPV vaccines has plummeted by over 60%, while flu and rabies vaccines are embroiled in price wars [1] - The strategy of "exchanging price for volume" has failed, leading to high inventory pressures and cash flow issues for companies [1] Group 2: Structural Challenges - The industry faces a dual challenge of oversupply in low-end markets and a lack of high-end products, with over 10 companies competing in the rabies and flu vaccine markets [2] - High-end vaccines like shingles and multi-valent vaccines are still dominated by foreign companies such as GSK [2] - Companies are caught in a dilemma of high R&D costs, long return cycles, and rapid market changes [2] Group 3: Strategies for Survival - Companies are increasing investment in multi-valent vaccines, with Watson Bio and Kangtai Bio leading the charge [3] - Zhifei Biological is building a product matrix to reduce dependency on single products, while Kangtai Bio is developing 13 pipeline products [3] - Collaborations for international market access, such as Kanghua Bio's partnership with HilleVax, are emerging as a survival strategy for smaller firms [3] Group 4: Future Outlook - The current dark period for the vaccine industry may serve as a starting point for value reassessment [4] - Companies that possess strong technology, diverse product portfolios, and global market access are likely to survive the supply-side cleansing [4] - The potential for Chinese vaccine companies to develop world-class products will determine the industry's future [4]